Welcome to RhodeIslandLifeScience.com

Our network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About Rhode Island's BioHistory

Through Rhode Island BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of Rhode Island.

Local News...

Free News Release Posting & Archiving Service


• LUNESTA(R) study of patients with insomnia and generalized anxiety disorder published  Sepracor announced the publication of a study of LUNESTA tablets in patients with insomnia and co-morbid generalized anxiety disorder in the May issue of the Archives of General Psychiatry.
  Sepracor Inc.  May 12, 2008  
  
  
• Idera Pharmaceuticals reports first quarter 2008 financial results  Idera Pharmaceuticals reported financial results for the quarter ended March 31, 2008. The Company reported a net loss of $2.2 million or $0.10 per share for the three months ended March 31, 2008, compared to a net loss of $2.5 million, or $0.12 per share for the same period in 2007.
  Idera Pharmaceuticals, Inc.  May 12, 2008  
  
  
• SIGA Technologies reports operating results for the first quarter of 2008  SIGA Technologies announced its results of operations for the first quarter of 2008. Revenues for the quarter ended March 31, 2008 were $2.0 million, virtually even with last year. All revenues for the quarter were derived from grants and contracts.
  SIGA Technologies, Inc.  May 12, 2008  
  
  
• Lilly completes final phase of its Indianapolis Biotechnology Complex  Eli Lilly and Company announced completion of the final phase of its $1 billion effort to further strengthen the company's biotechnology research and development capabilities.
  Eli Lilly and Company  May 12, 2008  
  
  
• Forest Laboratories and Daiichi Sankyo announce the termination of agreement  Forest Laboratories and Daiichi Sankyo announced that they have terminated their co-promotion agreement for AZOR(TM), Daiichi Sankyo's fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil.
  Forest Laboratories, Inc.  May 12, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Senior Toxicologist SNBL USA, Ltd. (WA)
• Technical Officer, Vaccine Stabilization PATH (WA)
• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/13/2008: 2008 Healthcare Investor & Corporate Development Conference
• 05/13/2008: Recruiting 2008 Conference & Expo
• 05/14/2008: Introduction to Oncology and Chemotherapy
• 05/14/2008: The Post-Approval Summit at Harvard
• 05/14/2008: Patent Issues in the Development of Biosimilar Medicines

More... | Submit Event | Event Advertising...